Publications

Back to Index

Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10

http://www.jimmunol.org/content/jimmunol/198/10/3809.full.pdf

Results from Kadmon’s Phase 2 dose-ranging clinical study of KD025 for the treatment of moderate to severe psoriasis